Abstract: Systems and methods for automatically tracking multi-Z horizons within seismic volumes are provided. A surface from a plurality of surfaces identified at different depths for a multi-Z horizon within a seismic volume is selected. A seed point corresponding to the selected surface is determined. The selected surface is tracked over new data points through the seismic volume. Tracking each new data point involves comparing a depth of the new data point with depths associated with other surfaces and determining whether the depth of the new data point honors a geological boundary rule for maintaining a relative depth position of each of the plurality of surfaces within the multi-Z horizon, based on the comparison. When the depth of the new data point honors the rule, the selected surface is extended to include the new data point and, when it does not, the new data point is discarded.

Abstract: A method for coordinating reactions of a virtual character with script spoken by a user involves specifying keywords in the script, making a first prediction of times for individual keywords and for responses by a virtual character, displaying the script, sensing the time that the user reaches a first keyword, recalculating the predictions based on the syllables in the script the time the user reaches the first keyword, sensing the time that the user reaches a second keyword, recalculating the predictions of times based on the syllables and time to second keyword, continuing to sense times and recalculating until a last keyword is reached, and causing specific actions and responses of the virtual character according to the recalculated predictions of times.

Abstract: A system for coordinating reactions of a virtual character with script spoken by a player in a video game or presentation, comprising an internet-connected server executing software and streaming video games or presentations to a player's computerized device. The system senses start of a dialogue between the player and the virtual character, displays a script for the player on a display of the computerized platform, prompts the player to speak the script. A timer then starts, or the system tracks an audio stream of the spoken script, determines where the player is in the script by the timer or the audio stream, and causes specific actions and responses of the virtual character according to pre-programmed association of actions and responses of the character to points of time or specific variations in the audio stream.

Abstract: A system for coordinating reactions of a virtual character with script spoken by a player in a video game or presentation, comprising an internet-connected server executing software and streaming video games or presentations to a player's computerized device. The system senses start of a dialogue between the player and the virtual character, displays a script for the player on a display of the computerized platform, prompts the player to speak the script. A timer then starts, or the system tracks an audio stream of the spoken script, determines where the player is in the script by the timer or the audio stream, and causes specific actions and responses of the virtual character according to pre-programmed association of actions and responses of the character to points of time or specific variations in the audio stream.

Abstract: A wearable reminder or gesture control device is provided using two different types of gestures obtained from two different types of sensors. The device outputs audio to a user but does not have a display, a keypad, or speech recognition software, therewith significantly reducing size, storage requirements and power consumption. Hence the device is suitable for use by the blind, persons with a speech impediment, visually impaired persons, and others who are unable to read small fonts.

Abstract: A wearable reminder device is provided using two different types of gestures obtained from two different types of sensors. The device outputs audio to a user but does not have a display, a keypad, or speech recognition software, therewith significantly reducing size, storage requirements and power consumption. Hence the device is suitable for use by the blind, persons with a speech impediment, visually impaired persons, and others who are unable to read small fonts.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: A wearable reminder device is provided using two different types of gestures obtained from two different types of sensors. The device outputs audio to a user but does not have a display, a keypad, or speech recognition software, therewith significantly reducing size, storage requirements and power consumption. Hence the device is suitable for use by the blind, persons with a speech impediment, visually impaired persons, and others who are unable to read small fonts.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example. Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compounds, as well as processes for their preparation.